These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: [Clinical study on treatment of liver fibrosis by different dosages of Salvia injection].
    Author: She SF, Huang XZ, Tong GD.
    Journal: Zhongguo Zhong Xi Yi Jie He Za Zhi; 2004 Jan; 24(1):17-20. PubMed ID: 14976882.
    Abstract:
    OBJECTIVE: To find the optimal dosage of Salvia injection in treating chronic hepatitis B caused liver fibrosis. METHODS: Sixty-four patients, whose diagnosis was confirmed as chronic hepatitis B caused liver fibrosis and differentiated by TCM typing as blood stasis blocking Collaterals type, were selected and randomly divided by lottery method into the large, middle and small dose of SI treated groups and the control group. All the patients were treated with modified Gexia Zhuyu Decoction, to the patients in the SI groups, 24 ml, 16 ml and 8 ml of SI were additionally administered by intravenous dripping respectively. The therapeutic course was 45 days. The clinical symptoms and signs; liver functional indexes as alanine transaminase (ALT), aspartate aminotransferase (AST) and albumin (ALB); and liver fibrosis indexes as procollagen type III (PC-III), collagen type IV (C-IV) and hyaluronic acid (HA), were measured before and after treatment. RESULTS: Different dosages of SI all could improve the clinical symptoms, and lower levels of ALT, AST, HA, PC-III and C-IV. Treatment of large dosage SI showed the best efficacy, superior to that of middle and small dosage SI, but no significant difference was found between the efficacy of the latter two. CONCLUSION: Anti-liver fibrosis effect of large dosage SI is better than that of middle or small dosage SI.
    [Abstract] [Full Text] [Related] [New Search]